Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10493077 Fused imidazo-piperidine JAK inhibitor compound

Patent 10493077 was granted and assigned to Theravance on December, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Theravance

Current Assignee

Theravance

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

10493077

Date of Patent

December 3, 2019

Patent Application Number

15966467

Date Filed

April 30, 2018

Patent Citations Received

‌

US Patent 12122773 Crystalline hydrate of a JAK inhibitor compound

‌

US Patent 11299492 JAK kinase inhibitor compounds for treatment of respiratory disease

‌

US Patent 11786517 Methods of treatment using a JAK inhibitor compound

‌

US Patent 11878977 JAK inhibitors containing a 4-membered heterocyclic amide

‌

US Patent 10836763 5 to 7 membered heterocyclic amides as JAK inhibitors

‌

US Patent 10844057 Process for preparing JAK inhibitors and intermediates thereof

‌

US Patent 10947229 Dimethyl amino azetidine amides as JAK inhibitors

‌

US Patent 11634419 Dimethyl amino azetidine amides as JAK inhibitors

...

Patent Primary Examiner

‌

Karen Cheng

Patent abstract

The invention provides a compound of formula 1

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10493077 Fused imidazo-piperidine JAK inhibitor compound

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API